Leica Biosystems is expanding its collaboration with AstraZeneca and Daiichi Sankyo to enhance AI-driven diagnostics in cancer, particularly focusing on non-small cell lung cancer (NSCLC) through the TROP2 Normalized Membrane Ratio (NMR) biomarker.
This initiative aims to develop an integrated system that includes an immunohistochemistry (IHC) assay and an image analysis algorithm, specifically for research purposes. The collaboration builds on a previous partnership that began in May 2025, leveraging AstraZeneca’s computational pathology algorithm, Quantitative Continuous Scoring (QCS), alongside Leica's digital pathology capabilities.
The focus on the TROP2 NMR biomarker will facilitate a more nuanced understanding of both membrane and cytoplasmic expression in NSCLC. This integrated approach is expected to lead to advancements in digital and computational pathology tools, potentially improving biomarker research and diagnostic strategies beyond traditional methods.
The collaboration will utilize various Leica platforms, such as the BOND RX research stainer and Aperio GT 450 scanner, to enable rapid development and global deployment of the computational algorithms. The TROP2 NMR algorithm will be accessible via the Aperio AI Store, allowing users to integrate these tools into a cohesive digital pathology ecosystem.
This strategic partnership underscores the necessity of collaboration in advancing cancer diagnostics, as noted by Gustavo Perez-Fernandez from Leica Biosystems. By merging expertise from all three organizations, the initiative aims to tackle complex challenges in biomarker research and enhance precision medicine approaches in oncology.